FGFR2 and cholangiocarcinoma: In intrahepatic CCA (iCCA), fibroblast growth factor receptor 2 (FGFR2) fusion, IDH1/2, BAP1, and ARID1A alterations have been considered as candidates for targeted therapy, and several trials are evaluating the therapeutic implications [6].